[go: up one dir, main page]

CA2001673A1 - Pharmaceutical composition containing piroxicam - Google Patents

Pharmaceutical composition containing piroxicam

Info

Publication number
CA2001673A1
CA2001673A1 CA2001673A CA2001673A CA2001673A1 CA 2001673 A1 CA2001673 A1 CA 2001673A1 CA 2001673 A CA2001673 A CA 2001673A CA 2001673 A CA2001673 A CA 2001673A CA 2001673 A1 CA2001673 A1 CA 2001673A1
Authority
CA
Canada
Prior art keywords
mass
parts
particle size
pharmaceutical composition
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2001673A
Other languages
French (fr)
Other versions
CA2001673C (en
Inventor
Pal Fekete
Denes Bezzegh
Istvan Simonyi
Biborka Maroshelyi
Katalin Zukovics
Janos Tombor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Pharmaceuticals PLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2001673A1 publication Critical patent/CA2001673A1/en
Application granted granted Critical
Publication of CA2001673C publication Critical patent/CA2001673C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising N-(2-piridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide as active ingredient and a process for preparing the same.
The composition is composed of 1 part by weight of N-(2-piridyl)-2-methyl-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide as active ingredient which at least in 90% by mass has a particle size of at most 30 /um, preferably 10 /um, if desired, 0.1 to 5.0 parts by mass, preferably 1 part by mass, of mannitol optionally of the same particle size, if desired, 0.005 to 0.15 parts by mass, preferably 0.06 to 0.1 parts by mass of silica optionally of the same particle size, 5 to 25 parts by mass, preferably 8 to 18 parts by mass, of spray-dried lactose which at least in 80% by mass has a particle size of 80 to 200 /um, if desired, 0.5 to 6.0 parts by mass, preferably 1.5 to 4.0 parts by mass, of a disintegrant, preferably corn starch, if desired, 0.005 to 0.05 parts by mass, preferably 0.01 to 0.02 parts by mass, of a surface active agent, preferably sodium lauryl sulfate, and if desired, 0.05 to 0.5 parts by mass, preferably 0.1 to 0.2 parts by mass of a lubricant, preferably magnesium stearate.
CA002001673A 1988-10-28 1989-10-27 Pharmaceutical composition containing piroxicam Expired - Fee Related CA2001673C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU885621A HU200926B (en) 1988-10-28 1988-10-28 Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules
HU5621/88 1988-10-28

Publications (2)

Publication Number Publication Date
CA2001673A1 true CA2001673A1 (en) 1990-04-28
CA2001673C CA2001673C (en) 1996-08-27

Family

ID=10970484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002001673A Expired - Fee Related CA2001673C (en) 1988-10-28 1989-10-27 Pharmaceutical composition containing piroxicam

Country Status (9)

Country Link
JP (1) JPH02172918A (en)
AT (1) AT399277B (en)
CA (1) CA2001673C (en)
DE (1) DE3936112C2 (en)
FR (1) FR2638357B1 (en)
GB (1) GB2224207B (en)
HU (1) HU200926B (en)
IL (1) IL92138A (en)
IT (1) IT1239542B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (en) * 1989-08-04 1997-08-20 田辺製薬株式会社 Ultrafine particle method for poorly soluble drugs
JP2964195B2 (en) * 1992-04-28 1999-10-18 エスエス製薬株式会社 Piroxicam tablets and method for producing the same
DE19603402A1 (en) * 1995-02-24 1996-08-29 Basf Ag Soft gelatin capsules
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
DK0914818T3 (en) * 1996-06-14 2005-07-04 Kyowa Hakko Kogyo Kk Intraoral fast disintegrable tablet
CA2327655C (en) * 1998-04-08 2010-03-09 Kyowa Hakko Kogyo Co., Ltd. Tablet production method and tablet
JP2000095674A (en) * 1998-09-22 2000-04-04 Sato Pharmaceutical Co Ltd Production of tablet having shortened intraoral disintegration time and apparatus therefor
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
EP1574215B1 (en) * 2002-12-16 2015-07-15 Kissei Pharmaceutical Co., Ltd. Solid drug for oral use
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006047493A2 (en) 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
ES2371414T3 (en) * 2005-07-25 2012-01-02 Otsuka Pharmaceutical Co., Ltd. ORAL PREPARATION TO MEASURE THE METABOLIC CAPACITY OF PYRIMIDINE.
MX2012006240A (en) 2009-12-02 2012-10-03 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them.
KR102105354B1 (en) 2012-08-20 2020-04-29 오츠카 세이야쿠 가부시키가이샤 Method for measuring carbohydrate metabolism ability, and composition for use in said method
KR20210014204A (en) 2013-03-15 2021-02-08 오츠카 세이야쿠 가부시키가이샤 Method of measuring insulin resistance with fatty acid combustion, and composition used herein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591584A (en) * 1968-08-27 1971-07-06 Pfizer Benzothiazine dioxides
GB1308533A (en) * 1969-06-02 1973-02-21 Pfizer Benzothiazine dioxides as anti-thombotic agents
JPS55129221A (en) * 1979-03-29 1980-10-06 Kaken Pharmaceut Co Ltd Preparation of oral preparation containing hardly soluble medicine
US4350689A (en) * 1980-02-15 1982-09-21 American Cyanamid Company Combinations of agents which give enhanced anti-inflammatory activity
US4434164A (en) * 1981-06-01 1984-02-28 Pfizer Inc. Crystalline benzothiazine dioxide salts
RO88420A (en) * 1983-04-25 1986-01-30 Pfizer Inc,Us PROCEDURE FOR THE PREPARATION OF PIROXICAN BASIC BATCHES EMPTY ON PHARMACEUTICAL SUPPORTS
DE3419128A1 (en) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen DIHYDROPYRIDINE PREPARATIONS AND METHOD FOR THE PRODUCTION THEREOF
CH663899A5 (en) * 1985-03-20 1988-01-29 Nestle Sa PROCESS FOR THE PREPARATION OF A COMPOSITION BASED ON A FINELY DIVIDED LOW HYDROSOLUBILITY ACTIVE INGREDIENT.
ES8603754A1 (en) * 1985-07-02 1986-01-01 Ferrer Int Coated peroxicam particles

Also Published As

Publication number Publication date
FR2638357B1 (en) 1993-10-22
DE3936112C2 (en) 1999-02-18
ATA247489A (en) 1994-09-15
FR2638357A1 (en) 1990-05-04
HUT51143A (en) 1990-04-28
IL92138A0 (en) 1990-07-12
JPH02172918A (en) 1990-07-04
DE3936112A1 (en) 1990-05-31
IT8922164A0 (en) 1989-10-27
IT8922164A1 (en) 1991-04-27
GB2224207B (en) 1992-06-10
GB2224207A (en) 1990-05-02
HU200926B (en) 1990-09-28
GB8924286D0 (en) 1989-12-13
AT399277B (en) 1995-04-25
IL92138A (en) 1994-08-26
IT1239542B (en) 1993-11-05
CA2001673C (en) 1996-08-27

Similar Documents

Publication Publication Date Title
CA2001673A1 (en) Pharmaceutical composition containing piroxicam
WO1997012583A3 (en) Stable compositions containing n-propargyl-1-aminoindan
RU96118271A (en) COMPOSITIONS CONTAINING FINE-CREATED NEBIVOL
HUT61324A (en) Process for producing rhombic cyclosporin consisting of globular particles and new pulmonary pharmaceutical compositions comprising same as active ingredient
CA2229597A1 (en) Oral fast-dissolving compositions for dopamine agonists
HUT61751A (en) Process for producing benzofuran derivatives and pharmaceutical compositions comprising such compounds as active ingredient
GB2264640B (en) Microcrystalline cellulose spheroids comprising hydromorphone and a sugar
CA2319308A1 (en) Pharmaceutical agents
CA2265766A1 (en) Rapidly disintegrating pellets
EP2011484A3 (en) Use of a dry powder composition of formoterol in the treatment of chronic obstructive pulmonary disease
CA2059263A1 (en) Composition comprising the (-) enantiomer of cis-4-amino-1-(2-hydromethyl-1,3-oxathiolan-5-yl)-(1h)-pyrimidine-2-one or an enriched composition thereof, and its uses as a pharmaceutical agent
PL299870A1 (en) 7-beta-[(z)-2-(2-amino-4-thiasolyl)-2-hydroxyiminoacetamide]-3-(1,2,3-triazol-4-yl)-thiomethylothio-3-cephemo-4-carboxylic hydrochloride, crystalline hydrate of 7-beta-[(z)-2-(2-amino-4-thiasolyl)-2-hydroxyiminoacetamide]-3-(1,2,3-triazol-4-yl)-thiomethylothio-3-cephemo-4-carboxylic hydrochloride, method of obtaining these compounds, pharmaceutical preparation and method of fighting against bacteriae
MY122124A (en) Solid pharmaceutical composition containing benzofurane derivatives
NO900370D0 (en) NIFEPIDINE-CONTAINING PHARMACEUTICAL MIXTURES AND PROCEDURES FOR PREPARING THEREOF.
HUP0102260A2 (en) Stabilization of compositions containing ace inhibitors using magnesium oxide
IL76332A0 (en) Solid medicament formulation containing nitrendipine and its preparation
HUT52078A (en) Herebicidal compositions comprising thiazole derivatives as active ingredient and process for producing the active ingredients
AU8188691A (en) The use of inositoltrisphosphate for the preparing of medicaments
MY113718A (en) Pharmaceutical formulation containing a hydrophobic active substance and an effervescent system, and process for the preparation of the formulation
WO2002056881A8 (en) Fenofibrate tablets
CA2063273A1 (en) Surfactant compositions and methods
CA2255064A1 (en) Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
HU895241D0 (en) Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient
GR3020828T3 (en) Sustained release suppositories and a process for preparation
HU900865D0 (en) Fungicidal compositions comprising 2-anilino-cyanopyridines and process for preparation of the active ingredient

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed